📊 EMMA Key Takeaways
Is Emmaus Life Sciences, Inc. (EMMA) a Good Investment?
Emmaus Life Sciences faces severe financial distress with negative stockholders' equity of -$59.5M, indicating the company is technically insolvent. The company is burning cash at an alarming rate (-$2.2M operating cash flow) while revenue has collapsed 43.7% year-over-year, and with only $293K in cash against $29.1M in long-term debt, insolvency risk is critical.
Emmaus Life Sciences shows severely stressed fundamentals: revenue fell 43.7% year over year, operating results remain negative, and net losses are extremely large relative to sales. While gross margin is unusually high, that strength is overwhelmed by weak scale, persistent cash burn, negative equity, and an acute liquidity shortfall that raises serious going-concern and refinancing risk.
Why Buy Emmaus Life Sciences, Inc. Stock? EMMA Key Strengths
- Exceptional gross margin of 92.8% demonstrates strong pricing power on products that generate sales
- Minimal capital expenditure requirements ($1K) suggests asset-light business model
- High gross profit of $8M on available revenue shows operational efficiency at production level
- Very high gross margin of 92.8%, indicating strong product-level pricing or manufacturing economics
- Low capital expenditure needs, which limits cash demands from fixed-asset investment
- Revenue base still exists despite losses, providing some operating platform to stabilize from
EMMA Stock Risks: Emmaus Life Sciences, Inc. Investment Risks
- Negative stockholders' equity of -$59.5M represents technical insolvency and likely covenant violations
- Catastrophic liquidity crisis with current ratio of 0.07x and only $293K cash against $80.2M total liabilities
- Revenue decline of 43.7% YoY combined with negative net margin of -64.4% indicates deteriorating market position and inability to cover operating costs
- Negative operating cash flow of -$2.2M and negative interest coverage ratio of -0.1x indicate inability to service debt obligations
- Zero insider trading activity in past 90 days may suggest lack of management confidence
- Current ratio of 0.07x and cash of only $293K indicate severe near-term liquidity pressure
- Negative stockholders equity of $59.49M and long-term debt of $29.07M reflect a highly impaired balance sheet
- Revenue decline of 43.7% and negative free cash flow suggest weak growth quality and poor earnings durability
Key Metrics to Watch
- Cash runway and monthly burn rate relative to remaining cash balance
- Debt restructuring negotiations or covenant amendment discussions
- Revenue stabilization or further decline trends
- Operating cash flow trajectory toward positive territory
- Equity infusion or financing announcements to address insolvency
- Quarterly revenue trend and whether sales contraction stabilizes or reverses
- Liquidity runway, including cash balance, operating cash flow, and any debt restructuring or capital raises
Emmaus Life Sciences, Inc. (EMMA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
EMMA Profit Margin, ROE & Profitability Analysis
EMMA vs Healthcare Sector: How Emmaus Life Sciences, Inc. Compares
How Emmaus Life Sciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Emmaus Life Sciences, Inc. Stock Overvalued? EMMA Valuation Analysis 2026
Based on fundamental analysis, Emmaus Life Sciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Emmaus Life Sciences, Inc. Balance Sheet: EMMA Debt, Cash & Liquidity
EMMA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Emmaus Life Sciences, Inc.'s revenue has declined by 28% over the 5-year period, indicating business contraction. The most recent EPS of $-0.10 indicates the company is currently unprofitable.
EMMA Revenue Growth, EPS Growth & YoY Performance
EMMA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.4M | -$1.1M | $0.03 |
| Q2 2025 | $2.8M | -$1.1M | $-0.02 |
| Q1 2025 | $2.4M | -$2.3M | $-0.04 |
| Q3 2024 | $5.0M | $67.0K | $-0.01 |
| Q2 2024 | $5.4M | -$1.6M | $-0.03 |
| Q1 2024 | $2.5M | -$3.5M | $-0.07 |
| Q3 2023 | $4.9M | $67.0K | $-0.01 |
| Q2 2023 | $4.3M | -$1.5M | $-0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Emmaus Life Sciences, Inc. Dividends, Buybacks & Capital Allocation
EMMA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Emmaus Life Sciences, Inc. (CIK: 0000822370)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EMMA
What is the AI rating for EMMA?
Emmaus Life Sciences, Inc. (EMMA) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are EMMA's key strengths?
Claude: Exceptional gross margin of 92.8% demonstrates strong pricing power on products that generate sales. Minimal capital expenditure requirements ($1K) suggests asset-light business model. ChatGPT: Very high gross margin of 92.8%, indicating strong product-level pricing or manufacturing economics. Low capital expenditure needs, which limits cash demands from fixed-asset investment.
What are the risks of investing in EMMA?
Claude: Negative stockholders' equity of -$59.5M represents technical insolvency and likely covenant violations. Catastrophic liquidity crisis with current ratio of 0.07x and only $293K cash against $80.2M total liabilities. ChatGPT: Current ratio of 0.07x and cash of only $293K indicate severe near-term liquidity pressure. Negative stockholders equity of $59.49M and long-term debt of $29.07M reflect a highly impaired balance sheet.
What is EMMA's revenue and growth?
Emmaus Life Sciences, Inc. reported revenue of $8.6M.
Does EMMA pay dividends?
Emmaus Life Sciences, Inc. does not currently pay dividends.
Where can I find EMMA SEC filings?
Official SEC filings for Emmaus Life Sciences, Inc. (CIK: 0000822370) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EMMA's EPS?
Emmaus Life Sciences, Inc. has a diluted EPS of $-0.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EMMA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Emmaus Life Sciences, Inc. has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EMMA stock overvalued or undervalued?
Valuation metrics for EMMA: ROE of N/A (sector avg: 15%), net margin of -64.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EMMA stock in 2026?
Our dual AI analysis gives Emmaus Life Sciences, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EMMA's free cash flow?
Emmaus Life Sciences, Inc.'s operating cash flow is $-2.2M, with capital expenditures of $1.0K. FCF margin is -25.8%.
How does EMMA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -64.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.07 (avg: 2).